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Background: Patient reported outcome measures used in studies of psoriatic arthritis (PsA) have been
found to be inadequate for determining the impact of the disease from the patient’s perspective.
Objective: To produce the PsAQoL, a PsA-specific quality of life (QoL) instrument, employing the needs
based model of QoL that would be relevant and acceptable to respondents, valid, and reliable.
Methods: Content was derived from qualitative interviews conducted with patients with PsA. Face and
content validity were assessed by field test interviews with a new sample of patients with PsA. A postal
survey was conducted to improve the scaling properties of the new measure. Finally, a test-retest postal
survey was used to identify the final measure and to test its scaling properties, reliability, internal
consistency, and validity.
Results: Analysis of the qualitative interview transcripts identified a 51 item questionnaire. Field test
interviews confirmed the acceptability and relevance of the measure. Analysis of data from the first postal
survey (n = 94) reduced the questionnaire to 35 items. Rasch analysis of data from the test-retest survey
(n = 286) identified a 20 item version of the PsAQoL with good item fit. This version had excellent internal
consistency (a= 0.91), test-retest reliability (0.89), and validity.
Conclusions: The PsAQoL is a valuable tool for assessing the impact of interventions for PsA in clinical
studies and trials. It is well accepted by patients, taking about three minutes to complete, is easy to
administer, and has excellent scaling and psychometric properties.
P
soriatic arthritis (PsA) is an inflammatory form of
arthritis that occurs in association with psoriasis and is
seronegative for rheumatoid factor. Gladman and
Espinoza suggest that PsA may occur in almost 1% of the
population.1 PsA can present as asymmetrical oligoarthritis
(in which few joints are affected); symmetrical polyarthritis
(indistinguishable from rheumatoid arthritis); and predomi-
nant spondylitis (with spinal involvement) which can be
indistinguishable from ankylosing spondylitis.2 The multi-
faceted nature of the presentation of the disease is subse-
quently mirrored in the complex manifestations of
impairment and limitation of activity experienced by
patients.3 4
The choice of outcome measure(s) for such complex
diseases presents a dilemma, often resulting in the need for
numerous instruments in an attempt to assess the different
impairments, activity limitations, and resulting participation
restriction experienced. Over the past decade several
researchers have attempted to employ existing patient
completed instruments to determine the impact of PsA. For
example, a number of authors have found that the Health
Assessment Questionnaire (HAQ) is not a useful measure for
assessing the impact of the disease. Blackmore and collea-
gues found that scores on the HAQ and the HAQ modified for
spondyloarthropathy were unrelated to PsA disease severity.5
An adapted version of the HAQ, specifically designed for use
in PsA was found not to be suitable for determining disability
associated with the condition.6
Duffy and colleagues attempted to validate the Arthritis
Impact Measurement Scale (AIMS) for patients with PsA.7
Unfortunately, they did not report on the reliability of the
scale—concentrating only on construct validity. The AIMS
sections were found to have low to moderate correlations
with clinical measures of function, disease activity, and
disease severity. Consequently, few conclusions could be
drawn from the study. Husted and associates conducted a
similar study with the adapted AIMS—AIMS2.8 Again, no
attempt was made to assess reliability, and low to moderate
correlations were found with measures of function and
disease activity. Correlations between AIMS2 scores and
disease severity were uniformly low (20.06 to 0.27). The
authors concluded that AIMS2 is less suitable for use with
patients with PsA than the original AIMS instrument.
The same authors explored the responsiveness of AIMS to
changes in traditional clinical indicators of health status.9
Unfortunately, they used AIMS at the first administration
and AIMS2 four years later. Only the pain component score
was significantly related to change in the number of active
joints, suggesting that the measure is unresponsive to clinical
changes in health status. In a later study,10 scores on the
HAQ, AIMS2 and SF-36 were unable to show differences in
health status between patients who had and had not received
surgery for their PsA. However, the groups were not matched
for disease severity.
Taccari and colleagues found predominantly low associa-
tions between indicators of disease activity and scores on
both the HAQ and AIMS in patients with PsA.11
Unsurprisingly, given its emphasis on physical disability,
the HAQ was unable to inform on the effect of the psoriatic
lesions experienced by patients.
Attempts have also been made to validate the Short Form-
36 (SF-36) for use in PsA.12 Again, unfortunately, no attempt
was made to measure the instrument’s reliability with this
patient group. Scores on the SF-36 were found to correlate
moderately with clinical indicators of function, pain, and
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arthritis activity. However, SF-36 scores were unrelated to
disease severity (particularly, psoriasis severity)—again
reflecting the bias of the instrument towards impairment
and physical disability.
The responsiveness to change of the HAQ, AIMS2, and SF-
36 in patients with PsA has also been investigated.4 All three
instruments performed poorly, although it appears that the
SF-36 was marginally more responsive. The lack of respon-
siveness of these instruments to articular changes suggests
that all three would be of limited value in a clinical trial.
To overcome these problems it was decided to develop a
PsA-specific outcome measure. The growing interest in the
assessment of quality of life (QoL), particularly in chronic
disabling conditions, argued in favour of focusing on this
outcome construct. The model adopted was the needs based
model of QoL,15–19 which has been successfully applied in the
development of disease-specific QoL measures for rheuma-
toid arthritis,20 ankylosing spondylitis,21 and systemic lupus
erythematosus.22 The measurement model argues that disease
related impairment and disability influence a person’s ability
to meet his or her needs. QoL is defined as the extent to
which needs are fulfilled. This model is particularly useful in
a condition such as PsA, as the reason for needs being
frustrated is irrelevant, allowing arthritic and dermatological
impacts to be summarised in a single outcome measure. QoL
assessment is intended to provide an accurate summary of
the impact of a disease from the perspective of the patient. It
is important to note that it is not intended to determine
disease severity or to aid in deciding on the most appropriate
intervention for individual patients.
This paper describes the development and validation of the
PsAQoL, a PsA-specific QoL instrument designed for use in
clinical trials and for assessing patient reported outcome in
routine clinical practice.
METHODS
Stages in instrument development
Table 1 lists the stages in the PsAQoL development
programme.
Patients
Different patient samples were employed at each stage of
instrument development and testing. Stages 1, 3, and 4
employed patients diagnosed with PsA currently attending
hospital outpatient clinics in Leeds. As a larger sample was
required for the second postal survey (stage 5), patients were
recruited with the help of the Psoriatic Arthropathy Alliance.
The questionnaire was included in a routine mailing to its
450 members. Participants in this survey were required to
provide information on the history of the PsA, aspects of its
current status, and current use of drugs.
I tem generation
The content of the PsAQoL was derived from unstructured,
qualitative interviews conducted with patients with PsA in
their own homes. This method of item generation fulfils a
basic requirement of QoL instruments—namely, that their
content should be generated from relevant patients.23 This is
because it ensures that the content of the final instrument is
relevant to the target population and that issues considered
important by patients are not omitted.
The interviews, which were audio recorded, were informal,
focused conversations and were designed to explore how PsA
affects the lives of patients. For example, interviewees were
encouraged to consider how functional limitations that they
experienced influenced their ability to meet their needs.
Transcripts were produced from the interview tapes, which
were then wiped clean to maintain confidentiality.
Information that would allow the identification of the
interviewee was also omitted from the typed transcripts.
Selection of items for the draft questionnaire
The interview transcripts were subjected to content analysis
to identify potential items for the questionnaire. Items were
selected for inclusion where they were relevant to the needs
model, were applicable to all potential respondents, reflected
a single idea, were unambiguous, and were short and simple.
Duplicated, idiosyncratic, and badly phrased items were
rejected and a draft questionnaire constructed from the
remaining items.
Field test methodology
Field test interviews were used to check on the relevance and
comprehensiveness of the draft PsAQoL and to see whether
patients could understand the questionnaire and complete it
without problems. This was the final stage at which the
wording of items could be changed to improve comprehen-
sion. It was also possible for interviewees to suggest
additional items. Interviews were conducted at rheumatology
outpatient clinics. Potential participants were approached in
the waiting room at the clinic and had the nature of the
project explained to them. If willing to take part, they were
interviewed one at a time in a quiet private office.
The questionnaire was completed in the presence of an
interviewer who noted whether the participants read the
instructions, had any obvious difficulties, or hesitated over
particular items. On completing the questionnaire, partici-
pants were invited to comment on the suitability of
questionnaire items, instructions, and response categories.
They were also asked specific questions about four of the
items to see how they were interpreted or to check on the
most appropriate wording. After this a second draft ques-
tionnaire was produced.
Postal survey 1
This survey was conducted primarily to reduce further the
number of items included in the draft PsAQoL. Patients with
PsA were sent a questionnaire booklet to complete consisting
of demographic questions and the PsAQoL. Rasch analysis
was conducted on the resulting data to identify items that
failed to fit the underlying measurement construct (QoL)
and/or that worked differentially by age or disease duration
(above or below the median). At this stage, only the most
grossly misfitting items or those with large differential item
functioning (DIF) were removed.
Postal survey 2
The purpose of the second postal survey was to identify the
final set of items to be included in the PsAQoL and to
determine the scaling properties, internal consistency, relia-
bility (reproducibility), and construct validity of the revised
measure.
As a larger sample was required for this survey, patients
were recruited with the help of the Psoriatic Arthropathy
Table 1 Stages in PsAQoL development
Stage Activity
1 Qualitative patient interviews
2 Content analysis of interview transcripts and
identification of potential items for PsAQoL
3 Field test patient interviews
4 Postal survey for item reduction
5 Test-retest postal survey to establish
reliability and construct validity
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Alliance. The questionnaire was included in a routine mailing
to its 450 members.
Members of the Psoriatic Arthropathy Alliance who
volunteered to participate in the survey were sent a revised
questionnaire booklet consisting of the demographic ques-
tionnaire (including questions about patient perceived dis-
ease activity and severity of illness), the current version of the
PsAQoL, the Nottingham Health Profile (NHP), and a reply
paid envelope. The NHP is a measure of perceived distress
that consists of six sections: energy level, pain, physical
mobility, sleep, social interactions, and emotional reactions.24
This measure was selected as the comparator measure as it is
generally well accepted by patients and has better psycho-
metric properties than the other generic health status
measures.24–26 Patients who completed and returned this
pack and gave permission to be approached again, were sent
a similar package timed to arrive two weeks later. It was not
possible to send follow up questionnaires as a condition of
the access to the society’s database was that its membership
should remain anonymous unless they responded to the first
mailing and specifically gave permission to be approached for
the test-retest mailing.
Data from the PsAQoL were again fitted to the Rasch
model to confirm that the items formed a unidimensional
scale, that they each represented a different amount of QoL
(hierarchical ordering), and that there was an absence of DIF.
The analyses also determined whether the scale operated at
the ordinal or interval level. Internal consistency, test-retest
reliability, and construct validity were then determined based
on the final PsAQoL item set.
Statistics
Rasch model
The application of the Rasch model ensures that the
fundamental scaling properties of an instrument (for
example, unidimensionality and level of measurement) are
assessed in addition to the traditional psychometric assess-
ments of reliability and external construct validity.27 In the
present context, the Rasch model adopts the premise that the
likelihood of a person affirming a particular item depends on
both the level of QoL of the person and on the level of QoL
represented by the item.
One way in which unidimensionality may be compromised
is through DIF.28 The basis of the DIF approach lies in the
item response function, the S-shaped trace of the proportion
of people at the same level of QoL who affirm an item. Under
the requirement that the ability under consideration is
unidimensional, if the item measures the same QoL across
groups then, except for random variations, the same curve is
found irrespective of the nature of the group for which a
function is plotted.28 Thus data from the draft PsAQoL
measures were fitted to the Rasch model and all items tested
for DIF by age and sex. Items that did not fit the model and
those displaying significant DIF were removed from the scale.
Fit to the model was assessed with a significance level of 0.01
to account for multiple testing.
Internal consistency (the degree of item interrelatedness)
was assessed by Cronbach’s alpha coefficients. A value of 0.70
or above was taken to be indicative of adequate internal
consistency.29 The reliability of the PsAQoL (an estimate of
the instrument’s reproducibility over time, assuming that no
change in condition has taken place) was assessed using the
test-retest method. Scores on the instrument at each
administration were correlated, with a Spearman rank
correlation coefficient of at least 0.85 considered necessary
to indicate that the PsAQoL would be suitable for use in a
clinical trial or for monitoring individual patients.30
Construct validity was assessed by relating scores on the
PsAQoL to those on the NHP and to perceived general health,
reported severity of illness, and patient perceived disease
activity. It was predicted that there would be moderate
associations between the PsAQoL and the NHP sections,
indicating that they assess related but different outcome
constructs. It was also suggested that QoL would be worse for
respondents reporting poorer general health or those con-
sidering their PsA to be severe.
Ethics
Ethical approval was given by the United Leeds Hospital Trust
ethics committee.
RESULTS
Findings from qualitative interviews (stage 1)
Interviews were conducted with 48 (32 male, 16 female)
patients with a mean (SD) age of 46.9 (13.4) years. Thirty
eight (79%) were married or cohabiting and 22 (46%) were
full time employed. Time since diagnosis ranged from 1 to 40
(mean 12.1) years, and 36 (75%) of the sample were
currently experiencing both psoriatic and arthritic symptoms.
Twenty nine (60%) interviewees were currently experiencing
a flare up of their condition.
The interviews lasted between 0.5 and 2.0 hours. PsA was
reported to have a major impact on many aspects of the
interviewees’ lives. The main issues raised could be cate-
gorised into four main experiences or events:
N Reaction to diagnosis: preoccupation with the illness and
grieving over loss of previous lifestyle.
N Life changes: reduced ability to fulfil personal roles, social
life, and work. Loss of motivation to take part in, and
reduced pleasure gained from, activities.
N Adaptation and acceptance: the need to adapt day to day
routines and to acknowledge that such changes are
necessary.
N Concerns for the future: uncertainty over future capabil-
ities, fear of potential worsening of the condition, and the
adverse effects of treatments and loss of independence.
It was clear from the interviews that as a result of PsA
several needs could not be fulfilled. These included needs for
control over the illness, stimulation, independence, sponta-
neity, companionship, communication, to feel valued, and to
have a purpose in life.
Selection of items for the draft questionnaire (stage 2)
As far as possible, items for the questionnaire consisted of
wording taken from the transcripts. In some cases it was
necessary to shorten the quotation, change the word order, or
express them as first person statements or in the present
tense. The item selection process yielded 169 potential
questionnaire items. Removal of duplicate, idiosyncratic,
and poorly phrased items resulted in a pool of 51 items for
the first version of the questionnaire. A dichotomous (‘‘true/
not true’’) response format was selected, as previous studies
had indicated that this was the most appropriate for such
questionnaires.31
Field testing for face and content validity (stage 3)
Fifteen patients (nine male, six female) were interviewed.
The sample had a mean (SD) age of 48.1 (10.8) years. All
interviewees were married or cohabiting and eight (53%)
were working full time. There was a mean (SD) period of 14.0
(10.1) years since diagnosis of PsA and 13 (87%) of the
sample were experiencing both psoriatic and arthritic
symptoms. Four (27%) of the sample were not currently
experiencing a flare up of their condition.
The interviewees took a median of five (range 3–
10) minutes to complete the 51 item questionnaire. The
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PsAQoL was considered to be well presented and acceptable
to patients. There did not appear to be any problems during
the completion of the questionnaire and no items were
determined to be inappropriate. During the interview,
patients were asked if there were any issues that had been
omitted from the questionnaire. Some issues were raised but
these tended to be idiosyncratic, such as difficulties
experienced with local public transport.
Although interviewees commented that the questionnaire
was relevant and covered pertinent issues they had experi-
enced because of their illness, problems were encountered
with eight of the items and some duplication of ideas was
found. Problems included some interviewee’s inability to
understand the word spontaneity used in one item, vaguely
expressed items, and others where there was a perceived lack
of specificity to PsA. Five items were removed from the
questionnaire and the wording of three more was changed as
a result of the interviews, resulting in a 46 item scale which
was taken forward for further testing.
Exploratory analysis—first postal survey (stage 4)
Demographic details of participants who took part in both
postal surveys are shown in table 2. The table also includes
patient reported information about health status.
Questionnaire packs were distributed to 120 patients and
returned by 94, a response rate of 78%. Rasch analyses were
performed on the data to identify items for which misfit or
DIF were most problematic. While some items were found to
misfit, DIF was minimal. As a result of these analyses, 11
items were removed from the PsAQoL, producing a 35 item
version that was taken forward to stage 5.
Internal and external construct validity and
reliability—second postal survey (stage 5)
Completed booklets were returned by 286 members of the
Psoriatic Arthropathy Alliance. Of those who responded, 237
(83%) also returned a completed questionnaire at time 2. As
this was a validation study, measures with one or more
missing responses were excluded from the analyses. Table 3
shows descriptive scores on the main outcome measures
(including the final 20 item PsAQoL—see below).
Fitting data to the Rasch model again identified misfit in
this larger sample. Fifteen additional items were removed
owing to misfit or DIF. The 20 item solution resulted in a
good overall item fit mean (SD) of 0.183 (1.115) and person
fit mean (SD) of 20.232 (0.807); and item trait interaction x2
of 96.1 (df = 80; p = 0.106). Individual item difficulty level
(QoL impact) ranged from 22.02 logits to +2.8 logits, and
individual item fit statistics ranged from p values of 0.954 to
0.017. A person separation index of 0.922 indicated that the
scale could differentiate four or more groups of patients along
the continuum. Table 4 gives the best and worst fitting items
of this solution.
The 20 item solution was tested again in the retest sample.
Once again this resulted in a good overall item fit mean (SD)
of 0.047 (1.508) and person fit mean (SD) of 20.205 (0.704);
and item trait interaction x2 of 79.9 (df = 60; p = 0.043).
Individual item difficulty level (QoL impact) ranged from
22.18 logits to +2.86 logits and individual item fit statistics
ranged from p values of 0.976 to 0.010. A person separation
index of 0.930 indicated that once again the scale could
differentiate four or more groups of patients along the
continuum. This second analysis confirmed the robustness of
the internal construct validity of the scale.
Reliabili ty and internal consistency of the PsAQoL
The test-retest Spearman rank correlation coefficient was
0.89, indicating that the measure has excellent reliability,
producing low levels of random measurement error
(table 5). In contrast, the reliability of the Health visual
analogue scale (VAS; 0.72), the QoL VAS (0.78), and that of
three of the NHP sections failed to meet the standard
required of instruments used in clinical trials. Internal
consistency of the PsAQoL was 0.91 at both administrations,
demonstrating an adequate degree of interconnectedness of
items.
External construct validity
Moderately high correlations were seen between the PsAQoL
and NHP section scores (table 6). The highest correlation was
with the energy level section (0.75)—a predictable result
reflecting the importance of fatigue on QoL in PsA. Similar
levels of correlations were also found between PsAQoL scores
and those on the Health and QoL VASs, suggesting that these
items were measuring related but different constructs than
the PsAQoL.
Scores on the PsAQoL were unrelated to sex, age, or marital
status or time since diagnosis. However, as expected,
employed respondents had better QoL (p,0.001).
Predictably, PsAQoL scores were also significantly related to
perceived current health (p,0.001) and to scores on the QoL
VAS (p,0.001) and those on the Health VAS (p,0.001).
Table 2 Characteristics and health status of respondents
participating in postal surveys
Postal survey 1
(n = 94)
Postal survey 2
(n = 286)
No % No %
Sex
Male 31 33 93 32.5
Female 62 67 193 67.5
Age (years)
Mean (SD) 48.0 (12.7) 50.6 (12.6)
Range 24–89 23–86
Marital status
Married/living as 59 63.4 213 74.7
Other 34 36.6 72 25.3
Employment status
Working full time 25 27.2 71 25.1
Working part time 12 13.0 36 12.7
Home maker 6 6.5 30 10.6
Other 49 53.3 146 51.6
Time since diagnosis (years)
Mean (SD) 13.8 (11.3) 12.5 (10.2)
Range 1–62 1–60
Perceived current health status
Very good 7 7.5 12 4.2
Good 22 23.7 99 34.9
Fair 43 46.2 129 45.4
Poor 21 22.6 44 15.4
Perceived current severity of psoriasis
Mild 40 43.5 125 45.6
Moderate 33 35.9 96 35.0
Quite severe 16 17.4 44 16.1
Severe 3 3.3 9 3.3
Perceived current severity of arthritis
Mild 19 20.4 55 19.9
Moderate 38 40.9 119 43.0
Quite severe 30 32.3 83 30.0
Severe 6 6.5 20 7.2
Current flare up of psoriasis?
Yes 41 48.2 111 41.0
No 44 51.8 160 59.0
Current flare up of arthritis?
Yes 57 62.0 149 53.6
No 35 38.0 129 46.4
Using treatment for psoriasis?
Yes 63 67.7 176 62.9
No 30 32.3 104 37.1
Using drugs for arthritis?
Yes 73 77.7 222 78.4
No 21 22.3 61 21.6
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PsAQoL scores were unrelated to whether or not facial skin
was affected, respondents were having a psoriasis flare up, or
they were currently being treated for their psoriasis. In
contrast, scores on the measure were worse when the hands
were affected by psoriasis (p,0.001) and were significantly
related to perceived severity of psoriasis (p,0.02). PsAQoL
scores were also significantly related to whether respondents
were having a flare up of arthritis (p,0.001), whether the
arthritis was being treated (p,0.01), and the perceived
severity of arthritis (p,0.001).
Figures 1 and 2 illustrate the associations between PsAQoL
scores and demographic and health status variables.
DISCUSSION
Perhaps one reason for the lack of success of patient reported
instruments used in studies of PsA is that the condition has
both rheumatic and dermatological impacts on patients. No
measure is available that is specific to PsA. The HAQ and
AIMS are measures developed for use with rheumatic
illnesses, and the SF-36 has been found to provide contra-
dictory scores for patients with psoriasis, suggesting either
that their health status is better than that of an average
population13 or that the impact of the illness on patients is
greater than that of arthritis, cancer, and myocardial
infarction.14 The SF-36 is a generic measure of health status
and the HAQ and AIMS are intended for use with all
rheumatic conditions, implying that their content may not
be particularly well focused on the issues of importance in
PsA. Furthermore, these measures focus primarily on
impairments and activity limitation (disability), adding
relatively little information to routine clinical indicators of
outcome. Consequently, they do not inform on the overall
impact of the condition and its treatment on the patient’s
QoL. The patients’ perspective is crucial when determin-
ing the acceptability of an intervention and associated
compliance.
The PsAQoL is based on a clear, conceptual model of QoL
that has been successfully used in the development of several
disease-specific QoL instruments, including measures for
rheumatoid arthritis, ankylosing spondylitis, and systemic
lupus erythematosus. The items in the measure largely
represent the words of individual patients with PsA and
were derived directly from qualitative, unstructured inter-
views. This method fulfils the basic requirement that QoL
instruments should be based on information derived directly
from patients and ensures that future respondents find the
instrument acceptable, comprehensive, and relevant to their
condition. The PsAQoL is quick and easy to complete—taking
less than five minutes, making it suitable for use in clinical
settings.
In rheumatology, Rasch analysis is increasingly seen as the
standard approach ensuring quality measurement.32 Fitting
data from the PsAQoL to the Rasch model confirmed a
unidimensional scale with good item stability over time, and
minimal DIF. Scales that fit the Rasch model have the added
advantage that scores can be transformed to the interval
level. This allows valid arithmetic operations such as the
calculation of change scores or effect sizes to be applied, an
important requirement for all outcome measures in musculo-
skeletal disorders.33
The test-retest reliability and internal consistency of the
PsAQoL are excellent, indicating that the instrument is
suitable for use in individual patients. For an instrument to
have construct validity it must be based on a model of the
construct assessed and be shown to have good reliability.34 As
these requirements are met for the PsAQoL it can be
concluded that the measure provides a valid assessment of
the construct defined in the model. Additional indications of
the validity of the PsAQoL were provided by the moderately
high correlations between PsAQoL scores and those on the
NHP (perceived distress), the Health VAS and the QoL VAS.
Scores on the PsAQoL were also related, as expected, to a
Table 3 Descriptive scores on the main outcome measures in postal survey 2
Measure No Median IQR Range
PsAQoL 263 9.0 5–13 0–20
Health VAS 273 49.0 32–69 0–99
QoL VAS 274 60.0 37–75 2–99
NHP
Energy level 278 66.7 33–100 0–100
Pain 273 50.0 25–89 0–100
Emotional reactions 276 11.1 0–33 0–100
Sleep 277 40.0 0–80 0–100
Social isolation 279 0.0 0–20 0–100
Physical mobility 274 37.5 13–50 0–100
NHPD 265 7.0 3–12 0–24
Table 4 Fit of the 20 item PsAQoL to the Rasch Model: Best and worst fitting items
Item Location Residual x2 p Value
Best
I can’t do the things I want to do 21.883 20.581 0.680 0.954
It’s too much effort to go out and see people 0.751 0.120 2.328 0.677
I take it out on people close to me 0.528 0.615 2.346 0.673
I feel like a prisoner in my own home 2.442 2.000 2.784 0.595
I’m unable to join in activities with friends or family 0.609 0.315 2.806 0.591
Worst
It takes me a long time to get going in the morning 21.626 20.482 6.205 0.184
I am easily irritated by other people 0.912 1.418 6.333 0.176
I have to keep stopping what I am doing to rest 21.256 20.141 7.968 0.093
I have to limit what I do each day 21.960 0.561 8.240 0.083
I often get angry with myself 20.393 2.206 12.041 0.018
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number of variables, including perceived current health,
whether the hands were affected by psoriasis, perceived
severity of both psoriasis and arthritis, and whether
respondents were having a flare up of their arthritis. It was
important to establish that the measure was related to both
the dermatological and rheumatological aspects of PsA.
It is acknowledged that the sample used in the second
postal survey was self selected and might have included some
subjects who did not have PsA. However, the psychometric
analyses did not suggest that there were problems with the
sample employed.
It also remains to be shown that the PsAQoL is responsive
to changes in QoL associated with effective interventions for
PsA. Such a property requires that a measure has good
reliability and validity, as has been demonstrated in the case
of the PsAQoL.
A criticism of disease-specific measures is that they do not
allow comparisons to be made across diseases and, conse-
quently, that they cannot form the basis of economic analyses
comparing the benefits of interventions for different diseases.
Modern psychometric techniques overcome this problem
through item banking.35 Where instruments are designed to
measure the same construct it is possible to ‘‘co-calibrate’’
them onto the same underlying metric (logit) scale. The
PsAQoL has been explicitly designed to be added to such an
item bank by an item selection process that, other things
being equal, selects items that are common with other
disease-specific scales. This then permits common item
equating of different scales and incorporation into a QoL
item bank.
It is concluded that the scaling and psychometric proper-
ties of the PsAQoL indicate that the instrument can be used
with confidence by researchers and clinicians. The instru-
ment represents the first patient based outcome measure
specific to PsA and (assuming that it proves to be responsive
to change in QoL, as suggested by its psychometric proper-
ties) it will be a valuable tool for assessing the impact of PsA
and its treatment in clinical settings, trials, and research
studies. Such an instrument will allow assessment of the
Table 5 Test-retest reliability for the main outcome
measures
Measure No
Test-retest
reliability
PsAQoL 211 0.89
Health VAS 232 0.72
QoL VAS 233 0.78
NHP
Energy level 229 0.76
Pain 225 0.87
Emotional reactions 223 0.79
Sleep 228 0.85
Social isolation 226 0.82
Physical mobility 221 0.88
NHPD 215 0.85
Table 6 Correlation between PsAQoL and comparator
measures
Comparator measure No
Correlation with
PsAQoL
Health VAS 253 20.64
QoL VAS 254 20.65
NHP
Energy level 257 0.75
Pain 252 0.68
Emotional reactions 255 0.69
Sleep 255 0.52
Social isolation 257 0.63
Physical mobility 255 0.72
NHPD 246 0.81
Figure 1 Associations between PsAQoL scores and disease severity and activity.
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effectiveness of interventions from the patient’s perspective.
Furthermore, the items included in the PsAQoL will be
incorporated into a rheumatology item bank, allowing
comparisons to be made between the QoL of patients with
different rheumatic conditions.
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N I feel tired whatever I do
N I find it difficult to have a good wash
N It’s too much effort to go out and see people
N I feel there’s no enjoyment in my life
N I feel I am losing my independence
N I often get angry with myself
N I can’t do the things I want to do
N I feel older than my years
N I’m unable to join in activities with my friends or family
N It limits the places I can go
N I have to push myself to do things
N I am easily irritated by other people
N I have to keep stopping what I’m doing to rest
N I feel dependent on others
N It takes me a long time to get going in the morning
N I take it out on people close to me
N I can’t do things on the spur of the moment
N I feel like a prisoner in my own home
N I have to limit what I do each day
N It puts a strain on my personal relationships
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